marimastat has been researched along with bay 12-9566 in 8 studies
| Studies (marimastat) | Trials (marimastat) | Recent Studies (post-2010) (marimastat) | Studies (bay 12-9566) | Trials (bay 12-9566) | Recent Studies (post-2010) (bay 12-9566) |
|---|---|---|---|---|---|
| 215 | 28 | 53 | 48 | 15 | 3 |
| Protein | Taxonomy | marimastat (IC50) | bay 12-9566 (IC50) |
|---|---|---|---|
| 72 kDa type IV collagenase | Homo sapiens (human) | 0.011 | |
| Stromelysin-1 | Homo sapiens (human) | 0.134 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 0.301 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albert, DH; Bouska, JJ; Curtin, ML; Dai, Y; Davidsen, SK; Elmore, IN; Florjancic, AS; Garland, RB; Goodfellow, CL; Guo, Y; Heyman, HR; Holms, JH; Marcotte, PA; Michaelides, MR; Morgan, DW; Stacey, JR; Steinman, DH; Tapang, P; Wada, CK | 1 |
| Nelson, NJ | 1 |
| Hande, KR; Nelson, AR; Rothenberg, ML | 1 |
| Brown, PD | 1 |
| Eckhardt, SG; Hidalgo, M | 1 |
| Heinemann, V | 1 |
| Didziapetriene, J; Kadziauskas, J; Stanciūte, D | 1 |
| Howes, JM; Laing, GD; Theakston, RD | 1 |
3 review(s) available for marimastat and bay 12-9566
| Article | Year |
|---|---|
Development of matrix metalloproteinase inhibitors in cancer therapy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Clinical Trials as Topic; Drugs, Investigational; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Protease Inhibitors; Pyrazines; Sulfonamides; Tetracycline; Tetracyclines; Thiophenes | 2001 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
[Expression of matrix metalloproteinases in patients with malignant tumors].
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Clinical Trials as Topic; Diphosphonates; Disease Progression; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hydroxamic Acids; Imidazoles; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasms; Organic Chemicals; Phenylalanine; Phenylbutyrates; Prognosis; Protease Inhibitors; Thiophenes; Time Factors; Tissue Inhibitor of Metalloproteinases | 2004 |
5 other study(ies) available for marimastat and bay 12-9566
| Article | Year |
|---|---|
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line; Formamides; Hydroxylamines; Macaca fascicularis; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Mice; Protease Inhibitors; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2002 |
Inhibitors of angiogenesis enter phase III testing.
Topics: Angiostatins; Animals; Antineoplastic Agents; Biphenyl Compounds; Clinical Trials, Phase III as Topic; Collagen; Endostatins; Endothelium, Vascular; Humans; Hydroxamic Acids; Metalloendopeptidases; Neovascularization, Pathologic; Organic Chemicals; Peptide Fragments; Phenylbutyrates; Plasminogen | 1998 |
New drugs on the horizon: matrix metalloproteinase inhibitors.
Topics: Antineoplastic Agents; Azepines; Biphenyl Compounds; Humans; Hydroxamic Acids; Metalloendopeptidases; Organic Chemicals; Phenylalanine; Phenylbutyrates; Protease Inhibitors; Pyrazines; Sulfonamides; Thiophenes | 1999 |
Ongoing trials with matrix metalloproteinase inhibitors.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Enzyme Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinase Inhibitors; Organic Chemicals; Phenylbutyrates | 2000 |
Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators.
Topics: Animals; Biphenyl Compounds; Chelating Agents; Chromatography, Gel; Chromatography, Liquid; Edetic Acid; Egtazic Acid; Ethylenediamines; Evaluation Studies as Topic; Hemorrhage; Hydroxamic Acids; Metalloproteases; Mice; Molecular Structure; Organic Chemicals; Phenylbutyrates; Protein Kinase Inhibitors; Pyrazines; Snake Bites; Statistics, Nonparametric; Sulfonamides; Viper Venoms | 2007 |